JP2014532072A - 眼疾患の治療 - Google Patents

眼疾患の治療 Download PDF

Info

Publication number
JP2014532072A
JP2014532072A JP2014535978A JP2014535978A JP2014532072A JP 2014532072 A JP2014532072 A JP 2014532072A JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014535978 A JP2014535978 A JP 2014535978A JP 2014532072 A JP2014532072 A JP 2014532072A
Authority
JP
Japan
Prior art keywords
hptpβ
binding agent
antibody
ecd
ecd binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014535978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532072A5 (enExample
Inventor
ケヴィン ピーターズ，
ケヴィン ピーターズ，
ロバート シャルウィッツ，
ロバート シャルウィッツ，
Original Assignee
エアピオ セラピューティックス， インコーポレイテッド
エアピオ セラピューティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアピオ セラピューティックス， インコーポレイテッド, エアピオ セラピューティックス， インコーポレイテッド filed Critical エアピオ セラピューティックス， インコーポレイテッド
Publication of JP2014532072A publication Critical patent/JP2014532072A/ja
Publication of JP2014532072A5 publication Critical patent/JP2014532072A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014535978A 2011-10-13 2012-10-15 眼疾患の治療 Withdrawn JP2014532072A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546708P 2011-10-13 2011-10-13
US61/546,708 2011-10-13
PCT/US2012/060263 WO2013056233A1 (en) 2011-10-13 2012-10-15 Treatment of ocular disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016178592A Division JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178593A Division JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2014532072A true JP2014532072A (ja) 2014-12-04
JP2014532072A5 JP2014532072A5 (enExample) 2015-12-24

Family

ID=48082580

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014535978A Withdrawn JP2014532072A (ja) 2011-10-13 2012-10-15 眼疾患の治療
JP2016178593A Withdrawn JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178592A Active JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2018103592A Pending JP2018131466A (ja) 2011-10-13 2018-05-30 眼疾患の治療
JP2018103593A Pending JP2018131467A (ja) 2011-10-13 2018-05-30 眼疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016178593A Withdrawn JP2016210812A (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2016178592A Active JP6259503B2 (ja) 2011-10-13 2016-09-13 眼疾患の治療
JP2018103592A Pending JP2018131466A (ja) 2011-10-13 2018-05-30 眼疾患の治療
JP2018103593A Pending JP2018131467A (ja) 2011-10-13 2018-05-30 眼疾患の治療

Country Status (11)

Country Link
US (5) US8999325B2 (enExample)
EP (2) EP3501536B1 (enExample)
JP (5) JP2014532072A (enExample)
CN (2) CN107080843A (enExample)
AU (1) AU2012323849B2 (enExample)
BR (1) BR112014008759A8 (enExample)
CA (1) CA2850824C (enExample)
ES (2) ES3059190T3 (enExample)
HK (2) HK1201438A1 (enExample)
MX (1) MX347226B (enExample)
WO (1) WO2013056233A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531259A (ja) * 2016-07-20 2019-10-31 エアーピオ セラピューティクス インコーポレイテッド ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
ES2782999T3 (es) 2009-11-06 2020-09-16 Aerpio Therapeutics Inc Composiciones y métodos para tratar la colitis
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint, Inc. Treatment of ocular disease
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
BR112016016411A2 (pt) * 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
CN106232120B (zh) 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
CN106491911A (zh) * 2016-10-24 2017-03-15 严成 一种治疗脉络膜血管瘤的中药
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
MX2022001433A (es) * 2019-08-06 2022-02-22 Hoffmann La Roche Tratamiento personalizado de enfermedades oftalmologicas.
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用
KR102932502B1 (ko) 2023-07-11 2026-03-04 재단법인 아산사회복지재단 Tie2을 과발현하는 혈관내피세포를 포함하는 망막 내 혈관신생 질환 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
IL132240A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
CA2368670C (en) 1999-03-26 2012-06-05 Chitra Suri Modulation of vascular permeability by means of tie2 receptor activators
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
HUP0302779A3 (en) 2000-06-23 2005-12-28 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US6316109B1 (en) 2000-09-21 2001-11-13 Ppg Industries Ohio, Inc. Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
US20040254197A1 (en) * 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
US20030158083A1 (en) * 2002-02-08 2003-08-21 The Procter & Gamble Company Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7718377B2 (en) * 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
JP2006210811A (ja) * 2005-01-31 2006-08-10 Nippon Steel Chem Co Ltd プリント配線板の製造方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
EP2518083A3 (en) 2005-12-15 2012-12-05 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008127727A1 (en) * 2007-04-13 2008-10-23 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2009003110A2 (en) * 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
BRPI0813966A8 (pt) * 2007-06-29 2016-02-10 Schering Corp Usos de mdl-1
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
CA2838846C (en) 2009-01-12 2018-06-19 Aerpio Therapeutics Inc. Compositions and methods for treating brain edema
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint, Inc. Treatment of ocular disease
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US10253094B2 (en) * 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
US10894824B2 (en) * 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533337A (ja) * 2006-04-07 2009-09-17 ザ プロクター アンド ギャンブル カンパニー ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRENT DIABETES REVIEWS, vol. 6, JPN6015050156, 2010, pages 304 - 312, ISSN: 0003216671 *
JOURNAL OF CELLULAR PHYSIOLOGY, vol. 216, JPN6015050157, 2008, pages 29 - 37, ISSN: 0003216672 *
昭和医会誌, vol. 第７０巻，第１号, JPN6015050154, 2010, pages 45 - 51, ISSN: 0003216670 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531259A (ja) * 2016-07-20 2019-10-31 エアーピオ セラピューティクス インコーポレイテッド ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体
JP7107914B2 (ja) 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2025011323A (ja) * 2016-07-20 2025-01-23 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体

Also Published As

Publication number Publication date
JP2016210812A (ja) 2016-12-15
CN107080843A (zh) 2017-08-22
EP3501536A1 (en) 2019-06-26
US20130095105A1 (en) 2013-04-18
HK1201438A1 (en) 2015-09-04
MX2014004449A (es) 2014-11-10
US20180044432A1 (en) 2018-02-15
BR112014008759A2 (pt) 2017-06-13
ES3059190T3 (en) 2026-03-19
EP3501536B1 (en) 2025-12-24
AU2012323849A1 (en) 2014-04-17
MX347226B (es) 2017-04-19
JP2018131466A (ja) 2018-08-23
ES2774972T3 (es) 2020-07-23
CA2850824A1 (en) 2013-04-18
US8999325B2 (en) 2015-04-07
EP2766044A4 (en) 2015-06-10
BR112014008759A8 (pt) 2017-09-12
EP2766044A1 (en) 2014-08-20
JP2018131467A (ja) 2018-08-23
US10329357B2 (en) 2019-06-25
CN104066448A (zh) 2014-09-24
AU2012323849B2 (en) 2017-04-20
US20200231703A1 (en) 2020-07-23
NZ623275A (en) 2016-05-27
CA2850824C (en) 2023-01-03
WO2013056233A1 (en) 2013-04-18
JP2016210811A (ja) 2016-12-15
HK1201196A1 (en) 2015-08-28
US20150232575A1 (en) 2015-08-20
US20200010565A1 (en) 2020-01-09
JP6259503B2 (ja) 2018-01-10
EP2766044B1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
JP6259503B2 (ja) 眼疾患の治療
JP6796184B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
US11136389B2 (en) Humanized monoclonal antibodies that target VE-PTP (HPTP-β)
AU2011224224B2 (en) Humanized and chimeric anti-properdin antibodies
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20151030

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20151118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160921

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20161013

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161021